Behçet's disease: A review

Journal of Dental Research

Volumn 84, Issue 3, 2005, Pages 209-222

  Al Otaibi, L M ^a   Porter, S R ^a   Poate, T W J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Beh et's; Disease; Genital; Ocular; Oral

Indexed keywords

ADULT; AUTOIMMUNE DISEASE; BEHCET DISEASE; CHILD; FEMALE; HUMAN; IMMUNOLOGY; MALE; PATHOPHYSIOLOGY; PROGNOSIS; REVIEW;

ADULT; AUTOIMMUNE DISEASES; BEHCET SYNDROME; CHILD; FEMALE; HUMANS; MALE; PROGNOSIS;

EID: 16844376681     PISSN: 00220345     EISSN: None     Source Type: Journal    
DOI: 10.1177/154405910508400302     Document Type: Review

References (199)

1. Akman-Demir G, Baykan-Kurt B, Serdaroglu P, Gurvit H, Yurdakul S, Yazici H, et al. (1996). Seven-year follow-up of neurologic involvement in Behçet syndrome. Arch Neurol 53:691-694.
2. Akoglu TF, Direskeneli H, Yazici H, Lawrence R (1990). TNF, soluble IL-2R and soluble CD-8 in Behçet's disease. J Rheumatol 17:1107-1108.
3. Akpolat T, Akkoyunlu M, Akpolat I, Dilek M, Odabas AR, Ozen S (2002). Renal Behçet's disease: a cumulative analysis. Semin Arthritis Rheum 31:317-337.
4. Aksu K, Kabasakal Y, Sayiner A, Keser G, Oksel F, Bilgic A, et al. (1999). Prevalences of hepatitis A, B, C and E viruses in Behçet's disease. Rheumatology (Oxford) 38:1279-1281.
5. Aktulga E, Altac M, Muftuoglu A, Ozyazgan Y, Pazarli H, Tuzun Y, et al. (1980). A double blind study of colchicine in Behçet's disease. Haematologica 65:399-402.
6. Akyol M, Dogan S, Kaptanoglu E, Ozcelik S (2002). Systemic isotretinoin in the treatment of Behçet's patients with arthritic symptoms and acne lesions. Clin Exp Rheumatol 20(4 Suppl):S-55.
7. al Aboosi MM, al Salem M, Saadeh A, al Jamal M, Hijawi M, Khammash M, et al. (1996). Behçet's disease: clinical study of Jordanian patients. Int J Dermatol 35:623-625.
8. al Dalaan AN, al Balaa SR, el Ramahi K, al Kawi Z, Bohlega S, Bahabri S, et al. (1994). Behçet's disease in Saudi Arabia. J Rheumatol 21:658-661.
9. Al Fahad SA, Al Araji AH (1999). Neuro-Behçet's disease in Iraq: a study of 40 patients. J Neurol Sci 170:105-111.
10. Al Rawi ZS, Neda AH (2003). Prevalence of Behçet's disease among Iraqis. Adv Exp Med Biol 528:37-41.
11. Alpsoy E, Aktekin M, Er H, Durusoy C, Yilmaz E (1998). A randomized, controlled and blinded study of papulopustular lesions in Turkish Behçet's patients. Int J Dermatol 37:839-842.
12. Alpsoy E, Durusoy C, Yilmaz E, Ozgurel Y, Ermis O, Yazar S, et al. (2002). Interferon alfa-2a in the treatment of Behçet disease: a randomized placebo-controlled and double-blind study. Arch Dermatol 138:467-471.
13. Aral O, Dilsen N, Konice M (1986). Positive skin pathergy reactivity as a genetic marker of Behçet's disease. In: Recent advances in Behçet's disease. Lehner T, Barnes CG, editors. London: Royal Society of Medical Services, pp. 173-175.
14. Aridogan BC, Yildirim M, Baysal V, Inaloz HS, Baz K, Kaya S (2003). Serum levels of IL-4, IL-10, IL-12, IL-13 and IFN-gamma in Behçet's disease. J Dermatol 30:602-607.
15. Ayata EM, Celik AF, Melikoglu M, Hamuryudan V, Yazici H (2002). The effect of smoking on oral ulcers (OU) of Behçet's syndrome (BS) (abstract). Berlin: 10th International Congress on Behçet's Disease.
16. Aykutlu E, Baykan B, Serdaroglu P, Gokyigit A, Akman-Demir G (2002). Epileptic seizures in Behçet disease. Epilepsia 43:832-835.
17. Bahram S, Spies T (1996). The MIC gene family. Res Immunol 147:328-333.
18. Bahram S, Bresnahan M, Geraghty DE, Spies T (1994). A second lineage of mammalian major histocompatibility complex class I genes. Proc Natl Acad Sci USA 91:6259-6263.
19. Baixauli A, Calvo J, Tamarit JJ, Campos C, Garcia S, Herrera A (2001). Behçet's disease: retrospective study. Ann Med Interna 18:405-410.
20. Bang D, Yoon KH, Chung HG, Choi EH, Lee ES, Lee S (1997a). Epidemiological and clinical features of Behçet's disease in Korea. Yonsei Med J 38:428-436.
21. Bang D, Chun YS, Haam IB, Lee ES, Lee S (1997b). The influence of pregnancy on Behçet's disease. Yonsei Med J 38:437-443.
22. Bang D, Lee JH, Lee ES, Lee S, Choi JS, Kim YK, et al. (2001). Epidemiologic and clinical survey of Behçet's disease in Korea: the first multicenter study. J Korean Med Sci 16:615-618.
23. Bang DS, Oh SH, Lee KH, Lee ES, Lee SN (2003). Influence of sex on patients with Behçet's disease in Korea. J Korean Med Sci 18:231-235.
24. Bank I, Duvdevani M, Livneh A (2003). Expansion of gammadelta T-cells in Behçet's disease: role of disease activity and microbial flora in oral ulcers. J Lab Clin Med 141:33-40.
25. Bardak Y (1999). Effects of age and sex on Behçet's disease. J Rheumatol 26:1008-1009.
26. Bayraktar Y, Balkanci F, Bayraktar M, Calguneri M (1997). Budd-Chiari syndrome: a common complication of Behçet's disease. Am J Gastroenterol 92:858-862.
27. Behçet's Disease Research Committee of Japan (1974). Behçet's disease: guide to diagnosis of Behçet's disease. Jpn J Ophthalmol 18:291-294.
28. Bhakta BB, Brennan P, James TE, Chamberlain MA, Noble BA, Silman AJ (1999). Behçet's disease: evaluation of a new instrument to measure clinical activity. Rheumatology (Oxford) 38:728-733.
29. Binder AI, Graham EM, Sanders MD, Dinning W, James DG, Denman AM (1987). Cyclosporin A in the treatment of severe Behçet's uveitis. Br J Rheumatol 26:285-291.
30. Bird Stewart JA (1986). Genetic analysis of families of patients with Behçet's syndrome: data incompatible with autosomal recessive inheritance. Ann Rheum Dis 45:265-268.
31. Blobner F (1937). Zur rezidivierenden Hypopyoniritis. Z Augenheilkunde 91:129-139.
32. Bonass W, Bird-Stewart J, Chamberlain MA (1986). Molecular studies in Behçet's syndrome. In: Recent advances in Behçet's disease. Lehner T, Barnes CG, editors. London: Royal Society of Medical Services, pp. 37-41.
33. Cakir N, Yazici H, Chamberlain MA, Barnes CG, Yurdakul S, Atasoy S, et al. (1991). Response to intradermal injection of monosodium urate crystals in Behçet's syndrome. Ann Rheum Dis 50:634-636.
34. Carletto A, Pacor ML, Biasi D, Caramaschi P, Zeminian S, Bellavite P, et al. (1997). Changes of neutrophil migration without modification of in vitro metabolism and adhesion in Behçet's disease. J Rheumatol 24:1332-1336.
35. Celenligil-Nazliel H, Kansu E, Ebersole JL (1999). Periodontal findings and systemic antibody responses to oral microorganisms in Behçet's disease. J Periodontol 70:1449-1456.
36. Cengiz M, Altundag MK, Zorlu AF, Gullu IH, Ozyar E, Atahan IL (2001). Malignancy in Behçet's disease: a report of 13 cases and a review of the literature. Clin Rheumatol 20:239-244.
37. Cetinel B, Obek C, Solok V, Yaycioglu O, Yazici H (1998). Urologic screening for men with Behçet's syndrome. Urology 52:863-865.
38. Chen YC, Chang HW (2001). Clinical characteristics of Behçet's disease in southern Taiwan. J Microbiol Immunol Infect 34:207-210.
39. Chikamori T, Doi YL, Yonezawa Y, Takata J, Kawamura M, Ozawa T (1990). Aortic regurgitation secondary to Behçet's disease. A case report and review of the literature. Eur Heart J 11:572-576.
40. Cho YH, Jung J, Lee KH, Bang D, Lee ES, Lee S (2003). Clinical features of patients with Behçet's disease and epididymitis. J Urol 170:1231-1233.
41. Choukri F, Chakib A, Himmich H, Hue S, Caillat-Zucman S (2001). HLA-B*51 and B*15 alleles confer predisposition to Behçet's disease in Moroccan patients. Hum Immunol 62:180-185.
42. Chun SI, Su WP, Lee S, Rogers RS III (1989). Erythema nodosum-like lesions in Behçet's syndrome: a histopathologic study of 30 cases. J Cutan Pathol 16:259-265.
43. Cohen R, Metzger S, Nahir M, Chajek-Shaul T (2002). Association of the MIC-A gene and HLA-B51 with Behçet's disease in Arabs and non-Ashkenazi Jews in Israel. Ann Rheum Dis 61:157-160.
44. Davatchi F, Shahram F, Akbarian M (1992). Epidemiology of Behçet's disease Iran. In: Rheumatology APPLAR 1992. Nasution AR, Darmawan J, Isbagio H, editors. Tokyo: Churchill Livingstone, pp. 95-98.
45. Davatchi F, Shahram F, Akbarian M (1997). Behçet's disease: analysis of 3443 cases. APLAR J Rheumatol 1:2-5.
46. Davatchi F, Shahram F, Nadji A, Jamshidi AR, Chams C, Chams H, et al. (2003). Influence of pathergy test on the accuracy of different diagnosis criteria for Behçet's disease. Adv Exp Med Biol 528:109-112.
47. Davies PG, Fordham JN, Kirwan JR, Barnes CG, Dinning WJ (1984). The pathergy test and Behçet's syndrome in Britain. Ann Rheum Dis 43:70-73.
48. Davies UM, Palmer RG, Denman AM (1988). Treatment with acyclovir does not affect orogenital ulcers in Behçet's syndrome: a randomized double-blind trial. Br J Rheumatol 27:300-302.
49. Demiroglu H, Dundar S (1997). Effects of age, sex, and initial presentation on the clinical course of Behçet's syndrome (letter). South Med J 90:567.
50. Demiroglu H, Ozcebe OI, Barista I, Dundar S, Eldem B (2000). Interferon alfa-2b, colchicine, and benzathine penicillin versus colchicine and benzathine penicillin in Behçet's disease: a randomised trial. Lancet 355:605-609.
51. Dilsen N, Konice M, Aral O (1986). Our diagnostic criteria of Behçet's disease-an overview. In: Recent advances in Behçet's disease. Lehner T, Barnes CG, editors. London: Academic Press, pp. 177-180.
52. Direskeneli H, Saruhan-Direskeneli G (2003). The role of heat shock proteins in Behçet's disease. Clin Exp Rheumatol 21:S44-S48.
53. Dunlop E (1979). Genital and other manifestations of Behçet's disease seen in venereological clinical practice. In: Behçet's syndrome: clinical and immunological features. Lehner T, Barnes G, editors. London: Academic Press, pp. 159-175.
54. Eglin RP, Lehner T, Subak-Sharpe JH (1982). Detection of RNA complementary to herpes-simplex virus in mononuclear cells from patients with Behçet's syndrome and recurrent oral ulcers. Lancet 2:1356-1361.
55. Ekmekci P, Boyvat A, Ozdemir E, Gurler A, Gurgey E (2003). Is long term observation of patients with recurrent aphthous stomatitis necessary? Clinical follow-up of 1238 cases. Adv Exp Med Biol 528:127-130.
56. Eldem B, Onur C, Ozen S (1998). Clinical features of pediatric Behçet's disease. J Pediatr Ophthalmol Strabismus 35:159-161.
57. Ergun T, Ince U, Eksioglu-Demiralp E, Direskeneli H, Gurbuz O, Gurses L, et al. (2001). HSP 60 expression in mucocutaneous lesions of Behçet's disease. J Am Acad Dermatol 45:904-909.
58. Estrach C, Mpofu S, Moots RJ (2002). Behçet's syndrome: response to infliximab after failure of etanercept. Rheumatology (Oxford) 41:1213-1214.
59. Fam AG, Siminovitch KA, Carette S, From L (1981). Neonatal Behçet's syndrome in an infant of a mother with the disease. Ann Rheum Dis 40:509-512.
60. Fresko I, Yazici H, Bayramicli M, Yurdakul S, Mat C (1993). Effect of surgical cleaning of the skin on the pathergy phenomenon in Behçet's syndrome. Ann Rheum Dis 52:619-620.
61. Freysdottir J, Lau S, Fortune F (1999). Gammadelta T cells in Behçet's disease (BD) and recurrent aphthous stomatitis (RAS). Clin Exp Immunol 118:451-457.
62. Ghayad E, Tohme A (1995). Behçet's disease in Lebanon: report of 100 cases. J Med Liban 43:2-7.
63. Gonzalez-Gay MA, Garcia-Porrua C, Branas F, Lopez-Lazaro L, Olivieri I (2000). Epidemiologic and clinical aspects of Behçet's disease in a defined area of Northwestern Spain, 1988-1997. J Rheumatol 27:703-707.
64. Goossens PH, Verburg RJ, Breedveld FC (2001). Remission of Behçet's syndrome with tumour necrosis factor alpha blocking therapy (case report). Ann Rheum Dis 60:637.
65. Groh V, Bahram S, Bauer S, Herman A, Beauchamp M, Spies T (1996). Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium. Proc Natl Acad Sci USA 93:12445-12450.
66. Gul A, Ozbek U, Ozturk C, Inanc M, Konice M, Ozcelik T (1996). Coagulation factor V gene mutation increases the risk of venous thrombosis in Behcet's disease. Br J Rheumatol 35:1178-1180.
67. Gul A, Inane M, Ocal L, Aral O, Konice M (2000). Familial aggregation of Behçet's disease in Turkey. Ann Rheum Dis 59:622-625.
68. Gurler A, Boyvat A, Tursen U (1997). Clinical manifestations of Behçet's disease: an analysis of 2147 patients. Yonsei Med J 38:423-427.
69. Hamuryudan V, Moral F, Yurdakul S, Mat C, Tuzun Y, Ozyazgan Y, et al. (1994). Systemic interferon alpha 2b treatment in Behçet's syndrome. J Rheumatol 21:1098-1100.
70. Hamuryudan V, Sonsuz A, Yurdakul S (1995). More on hepatitis C virus and Behçet's syndrome. N Engl J Med 333:322-323.
71. Hamuryudan V, Ozyazgan Y, Hizli N, Mat C, Yurdakul S, Tuzun Y, et al. (1997). Azathioprine in Behçet's syndrome: effects on long-term prognosis. Arthritis Rheum 40:769-774.
72. Hasan A, Childerstone A, Pervin K, Shinnick T, Mizushima Y, van der Zee R, et al. (1995). Recognition of a unique peptide epitope of the mycobacterial and human heat shock protein 65-60 antigen by T cells of patients with recurrent oral ulcers. Clin Exp Immunol 99:392-397.
73. Hasan A, Fortune F, Wilson A, Warr K, Shinnick T, Mizushima Y, et al. (1996). Role of gamma delta T cells in pathogenesis and diagnosis of Behçet's disease. Lancet 347:789-794.
74. Haugeberg G, Velken M, Johnsen V (2004). Successful treatment of genital ulcers with infliximab in Behçet's disease. Ann Rheum Dis 63:744-745.
75. Hirohata S, Oka H, Mizushima Y (1992). Streptococcal-related antigens stimulate production of IL6 and interferon-gamma by T cells from patients with Behçet's disease. Cell Immunol 140:410-419.
76. Hirohata S, Suda H, Hashimoto T (1998). Low-dose weekly methotrexate for progressive neuropsychiatric manifestations in Behçet's disease. J Neurol Sci 159:181-185.
77. Huong DL, Wechsler B, Papo T, de Zuttere D, Bletry O, Hernigou A, et al. (1997). Endomyocardial fibrosis in Behçet's disease. Ann Rheum Dis 56:205-208.
78. Imai H, Motegi M, Mizuki N, Ohtani H, Komatsuda A, Hamai K, et al. (1997). Mouth and genital ulcers with inflamed cartilage (MAGIC syndrome): a case report and literature review. Am J Med Sci 314:330-332.
79. Imai Y (1971). Studies on prognosis and symptoms of Behçet's disease in long term observation. Jpn J Clin Ophthalmol 25:661-694.
80. Inaloz HS, Evereklioglu C, Unal B, Kirtak N, Eralp A, Inaloz SS (2004). The significance of immunohistochemistry in the skin pathergy reaction of patients with Behçet's syndrome. J Eur Acad Dermatol Venereol 18:56-61.
81. International Study Group for Behçet's Disease (1990). Criteria for diagnosis of Behçet's disease. Lancet 335:1078-1080.
82. Ioakimidis D, Georganas C, Panagoulis C, Gournizakis A, Iliopoulos A, Kremastinos D, et al. (1993). A case of Adamantiadis-Behçet's syndrome presenting as myocardial infarction. Clin Exp Rheumatol 11:183-186.
83. Isogai E, Ohno S, Kotake S, Isogai H, Tsurumizu T, Fujii N, et al. (1990a). Chemiluminescence of neutrophils from patients with Behçet's disease and its correlation with an increased proportion of uncommon serotypes of Streptococcus sanguis in the oral flora. Arch Oral Biol 35:43-48.
84. Isogai E, Ohno S, Takeshi K, Yoshikawa K, Tsurumizu T, Isogai H, et al. (1990b). Close association of Streptococcus sanguis uncommon serotypes with Behçet's disease. Bifidobacteria Microflora 9:27-41.
85. Jaber L, Milo G, Halpern GJ, Krause I, Weinberger A (2002). Prevalence of Behçet's disease in an Arab community in Israel. Ann Rheum Dis 61:365-366.
86. Jankowski J, Crombie I, Jankowski R (1992). Behçet's syndrome in Scotland. Postgrad Med J 68:566-570.
87. Kaklamani VG, Vaiopoulos G, Markomichelakis N, Kaklamanis P (2000). Recurrent epididymo-orchitis in patients with Behçet's disease. J Urol 163:487-489.
88. Kaklamani VG, Tzonou A, Markomichelakis N, Papazoglou S, Kaklamanis PG (2003). The effect of smoking on the clinical features of Adamantiades- Behçet's disease. Adv Exp Med Biol 528:323-327.
89. Kaneko F, Oyama N, Nishibu A (1997). Streptococcal infection in the pathogenesis of Behçet's disease and clinical effects of minocycline on the disease symptoms. Yonsei Med J 38:444-454.
90. Kaneko F, Takahashi Y, Muramatsu Y, Miura Y (1985). Immunological studies on aphthous ulcer and erythema nodosum-like eruptions in Behçet's disease. Br J Dermatol 113:303-312.
91. Kaneko S, Suzuki N, Yamashita N, Nagafuchi H, Nakajima T, Wakisaka S, et al. (1997). Characterization of T cells specific for an epitope of human 60-kD heat shock protein (hsp) in patients with Behçet's disease (BD) in Japan. Clin Exp Immunol 108:204-212.
92. Kari JA, Shah V, Dillon MJ (2001). Behçet's disease in UK children: clinical features and treatment including thalidomide. Rheumatology (Oxford) 40:933-938.
93. Katzenellenbogen I, Feuerman EJ (1965). Beitrag zum Morbus Behçet Die Bedeutung der spezifschen. Hauthyperraktivität und der Behçetin Reaktion Hautarzt 16:13-18.
94. Kaya TI, Dur H, Tursen U, Gurler A (2002). Association of class I HLA antigens with the clinical manifestations of Turkish patients with Behçet's disease. Clin Exp Dermatol 27:498-501.
95. Kilbourne ED, Horsefall FL (1951). Primary herpes simplex virus infection of the adult. Arch Intern Med 88:495-502.
96. Kilmartin DJ, Forrester JV, Dick AD (1998). Tacrolimus (FK506) in failed cyclosporin A therapy in endogenous posterior uveitis. Ocul Immunol Inflamm 6:101-109.
97. Kim DK, Chang SN, Bang D, Lee ES, Lee S (1994). Clinical analysis of 40 cases of childhood-onset Behçet's disease. Pediatr Dermatol 11:95-101.
98. Koc Y, Gullu I, Akpek G, Akpolat T, Kansu E, Kiraz S, et al. (1992). Vascular involvement in Behçet's disease. J Rheumatol 19:402-410.
99. Kone-Paut I, Yurdakul S, Bahabri SA, Shafae N, Ozen S, Ozdogan H, et al. (1998). Clinical features of Behçet's disease in children: an international collaborative study of 86 cases. J Pediatr 132:721-725.
100. Kone-Paut I, Gorchakoff-Molinas A, Weschler B, Touitou I (2002). Paediatric Behçet's disease in France. Ann Rheum Dis 61:655-656.
101. Kontogiannis V, Powell RJ (2000). Behçet's disease. Postgrad Med J 76:629-637.
102. Kotter I, Gunaydin I, Stubiger N, Yazici H, Fresko I, Zouboulis CC, et al. (2001). Comparative analysis of the association of HLA-B*51 suballeles with Behçet's disease in patients of German and Turkish origin. Tissue Antigens 58:166-170.
103. Krause I, Uziel Y, Guedj D, Mukamel M, Molad Y, Amit M, et al. (1998). Mode of presentation and multisystem involvement in Behçet's disease: the influence of sex and age of disease onset. J Rheumatol 25:1566-1569.
104. Krause I, Uziel Y, Guedj D, Mukamel M, Harel L, Molad Y, et al. (1999). Childhood Behçet's disease: clinical features and comparison with adult-onset disease. Rheumatology (Oxford) 38:457-462.
105. Krause I, Mader R, Sulkes J, Paul M, Uziel Y, Adawi M, et al. (2001). Behçet's disease in Israel: the influence of ethnic origin on disease expression and severity. J Rheumatol 28:1033-1036.
106. Kural-Seyahi E, Fresko I, Seyahi N, Ozyazgan Y, Mat C, Hamuryudan V, et al. (2003). The long-term mortality and morbidity of Behçet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore) 82:60-76.
107. Lakhanpal S, O'Duffy JD, Lie J (1988). Pathology. In: Behçet's disease: a contemporary synopsis. Plotkin G, Calabro J, O'Duffy J, editors. New York: Futura Publishing Company, pp. 102-142.
108. Lamb JR, Young DB (1990). T cell recognition of stress proteins. A link between infectious and autoimmune disease. Mol Biol Med 7:311-321.
109. Lannuzel A, Lamaury I, Charpentier D, Caparros-Lefebvre D (2002). Neurological manifestations of Behçet's disease in a Caribbean population: clinical and imaging findings. J Neurol 249:410-418.
110. Larkin G, Lightman S (1999). Mycophenolate mofetil. A useful immunosuppressive in inflammatory eye disease. Ophthalmology 106:370-374.
111. Lehner T (1997). The role of heat shock protein, microbial and autoimmune agents in the aetiology of Behçet's disease. Int Rev Immunol 14:21-32.
112. Lehner T, Lavery E, Smith R, van der Zee R, Mizushima Y, Shinnick T (1991). Association between the 65-kilodalton heat shock protein, Streptococcus sanguis, and the corresponding antibodies in Behçet's syndrome. Infect Immun 59:1434-1441.
113. Lesprit P, Wechsler B, Piette JC, Du-Boutin LT, Godeau P, Alhenc-Gelas M, et al. (1995). Activated protein C resistance caused by factor V Arg 506->Gln mutation has no role in thrombotic manifestations of Behçet's disease (letter). Ann Rheum Dis 54:860.
114. Main DM, Chamberlain MA (1992). Clinical differentiation of oral ulceration in Behçet's disease. Br J Rheumatol 31:767-770.
115. Mammo L, Al Dalaan A, Bahabri SS, Saour JN (1997). Association of factor V Leiden with Behçet's disease. J Rheumatol 24:2196-2198.
116. Marsal S, Falga C, Simeon CP, Vilardell M, Bosch JA (1997). Behçet's disease and pregnancy relationship study. Br J Rheumatol 36:234-238.
117. Martini A (1995). Behçet's disease and Takayasu's disease in children. Curr Opin Rheumatol 7:449-454.
118. Mason RM, Barnes CG (1969). Behçet's syndrome with arthritis. Ann Rheum Dis 28:95-103.
119. Masuda K, Nakajima A, Urayama A, Nakae K, Kogure M, Inaba G (1989). Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behçet's disease. Lancet 1:1093-1096.
120. Mege JL, Dilsen N, Sanguedolce V, Gul A, Bongrand P, Roux H, et al. (1993). Overproduction of monocyte derived tumor necrosis factor alpha, interleukin (IL) 6, IL-8 and increased neutrophil superoxide generation in Behçet's disease. A comparative study with familial Mediterranean fever and healthy subjects. J Rheumatol 20:1544-1549.
121. Melikoglu M, Altiparmak MR, Fresko I, Tunc R, Yurdakul S, Hamuryudan V, et al. (2001). A reappraisal of amyloidosis in Behçet's syndrome. Rheumatology (Oxford) 40:212-215.
122. Melikoglu M, Fresko I, Mat C (2002). A double blind placebo controlled trial of etanercept on mucocutaneous lesions of Behçet's syndrome (abstract). Berlin: 10th International Congress on Behçet's Disease.
123. Mishima S, Masuda K, Izawa Y (1979). Behçet's disease in Japan (abstract). Trans Am Ophthalmol Soc 77:225.
124. Mizuki N, Ohno S (1996). Immunogenetic studies of Behçet's disease. Rev Rhum Engl Ed 63:520-527.
125. Mizuki N, Inoko H, Sugimura K, Nishimura K, Nakamura S, Tanaka H, et al. (1992). RFLP analysis in the TNF-beta gene and the susceptibility to alloreactive NK cells in Behçet's disease. Invest Ophthalmol Vis Sci 33:3084-3090.
126. Mizuki N, Ohno S, Sato T, Ishihara M, Miyata S, Nakamura S, et al. (1995). Microsatellite polymorphism between the tumor necrosis factor and HLA-B genes in Behçet's disease. Hum Immunol 43:129-135.
127. Mizuki N, Inoko H, Ohno S (1997). Molecular genetics (HLA) of Behçet's disease. Yonsei Med J 38:333-349.
128. Mizuki N, Ota M, Yabuki K, Katsuyama Y, Ando H, Palimeris GD, et al. (2000). Localization of the pathogenic gene of Behçet's disease by microsatellite analysis of three different populations. Invest Ophthalmol Vis Sci 41:3702-3708.
129. Mizuki N, Ota M, Katsuyama Y, Yabuki K, Ando H, Shiina T, et al. (2001a). HLA-B*51 allele analysis by the PCR-SBT method and a strong association of HLA-B*5101 with Japanese patients with Behçet's disease. Tissue Antigens 58:181-184.
130. Mizuki N, Yabuki K, Ota M, Verity D, Katsuyama Y, Ando H, et al. (2001b). Microsatellite mapping of a susceptible locus within the HLA region for Behçet's disease using Jordanian patients. Hum Immunol 62:186-190.
131. Mizuki N, Ota M, Katsuyama Y, Yabuki K, Ando H, Shiina T, et al. (2002). Sequencing-based typing of HLA-B*51 alleles and the significant association of HLA-B*5101 and -B*5108 with Behçet's disease in Greek patients. Tissue Antigens 59:118-121.
132. Mizushima Y (1986). Chemotaxis and phagocytosis of leukocytes in Behçet's disease. In: Recent advances in Behçet's disease. Lehner T, Barnes CG, editors. London: Royal Society of Medical Services, pp. 85-87.
133. Mizushima Y, Matsumura N, Mori M, Shimizu T, Fukushima B, Mimura Y, et al. (1977). Colchicine in Behçet's disease (letter). Lancet 2:1037.
134. Mizushima Y, Matsuda T, Hoshi K, Ohno S (1988). Induction of Behçet's disease symptoms after dental treatment and streptococcal antigen skin test. J Rheumatol 15:1029-1030.
135. Mogulkoc N, Burgess MI, Bishop PW (2000). Intracardiac thrombus in Behçet's disease: a systematic review. Chest 118:479-487.
136. Morelli S, Perrone C, Ferrante L, Sgreccia A, Priori R, Voci P, et al. (1997). Cardiac involvement in Behçet's disease. Cardiology 88:513-517.
137. Mousa AR, Marafie AA, Rifai KM, Dajani AI, Mukhtar MM (1986). Behçet's disease in Kuwait, Arabia. A report of 29 cases and a review. Scand J Rheumatol 15:310-332.
138. Muhaya M, Lightman S, Ikeda E, Mochizuki M, Shaer B, McCluskey P, et al. (2000). Behçet's disease in Japan and in Great Britain: a comparative study. Ocul Immunol Inflamm 8:141-148.
139. Namba K, Ueno T, Okita M (1986). Behçet's disease and streptococcal infection. Jpn J Ophthalmol 30:385-401.
140. Nazzaro P (1966). Cutaneous manifestations of Behçet's disease. In: International Symposium on Behçet's Disease in Rome. Monacelli M, Nazzaro P, editors. Karger: Basel, pp. 1-24.
141. Nishiyama M, Nakae K, Umehara T (2001). A study of familial occurrence of Behçet's disease with and without ocular lesions. Jpn J Ophthalmol 45:313-316.
142. O'Duffy JD (1974). Suggested criteria for diagnosis of Behçet's disease (abstract). J Rheumatol 1(Suppl 1):18.
143. O'Duffy JD (1978). Summary of International Symposium on Behçet's Disease. Istanbul, September 29-30, 1977. J Rheumatol 5:229-233.
144. O'Duffy JD (1994). Behçet's disease. Curr Opin Rheumatol 6:39-43.
145. O'Duffy JD, Robertson DM, Goldstein NP (1984). Chlorambucil in the treatment of uveitis and meningoencephalitis of Behçet's disease. Am J Med 76:75-84.
146. Oguz A, Sametoglu F, Erdogan S (1995). More on hepatitis C and Behçet's syndrome. N Engl J Med 333:322-323.
147. Oner AF, Gurgey A, Gurler A, Mesci L (1998). Factor V Leiden mutation in patients with Behçet's disease. J Rheumatol 25:496-498.
148. Orloff LA, Orloff MJ (1999). Budd-Chiari syndrome caused by Behçet's disease: treatment by side-to-side portacaval shunt. J Am Coll Surg 188:396-407.
149. Pande I, Uppal SS, Kailash S, Kumar A, Malaviya AN (1995). Behçet's disease in India: a clinical, immunological, immunogenetic and outcome study. Br J Rheumatol 34:825-830.
150. Paul M, Klein T, Krause I, Molad Y, Narinsky R, Weinberger A (2001). Allelic distribution of HLA-B*5 in HLA-B5-positive Israeli patients with Behçet's disease. Tissue Antigens 58:185-186.
151. Porter S, Scully C (2002). Aphthous ulcers: recurrent. Clin Evid 8:1397-1403.
152. Porter SR, Scully C, Pedersen A (1998). Recurrent aphthous stomatitis. Crit Rev Oral Biol Med 9:306-321.
153. Raziuddin S, Al Dalaan A, Bahabri S, Siraj AK, al Sedairy S (1998). Divergent cytokine production profile in Behçet's disease. Altered Th1/Th2 cell cytokine pattern. J Rheumatol 25:329-333.
154. Robertson LP, Hickling P (2001). Treatment of recalcitrant orogenital ulceration of Behçet's syndrome with infliximab. Rheumatology (Oxford) 40:473-474.
155. Russell AI, Lawson WA, Haskard DO (2001). Potential new therapeutic options in Behçet's syndrome. BioDrugs 15:25-35.
156. Saenz A, Ausejo M, Shea B, Wells G, Welch V, Tugwell P (2004). Pharmacotherapy for Behçet's syndrome (Cochrane Review). The Cochrane Library. Vol. 2. Chichester, UK: John Wiley & Sons, Ltd.
157. Sanz L, Gonzalez-Escribano F, de Pablo R, Nunez-Roldan A, Kreisler M, Vilches C (1998). HLA-Cw*1602: a new susceptibility marker of Behçet's disease in southern Spain. Tissue Antigens 51:111-114.
158. Saylan T, Mat C, Fresko I, Melikoglu M (1999). Behçet's disease in the Middle East. Clin Dermatol 17:209-223.
159. Sfikakis PP (2002). Behçet's disease: a new target for anti-tumour necrosis factor treatment. Ann Rheum Dis 61(Suppl 2):ii51-ii53.
160. Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN (2001). Effect of infliximab on sight-threatening panuveitis in Behçet's disease. Lancet 358:295-296.
161. Sfikakis PP, Kaklamanis PH, Elezoglou A, Katsilambros N, Theodossiadis PG, Papaefthimiou S, et al. (2004). Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behçet disease. Ann Intern Med 140:404-406.
162. Shah SS, Lowder CY, Schmitt MA, Wilke WS, Kosmorsky GS, Meisler DM (1992). Low-dose methotrexate therapy for ocular inflammatory disease. Ophthalmology 99:1419-1423.
163. Sharquie KE, Najim RA, Abu-Raghif AR (2002). Dapsone in Behçet's disease: a double-blind, placebo-controlled, cross-over study. J Dermatol 29:267-279.
164. Shek LP, Lim DL (2002). Thalidomide in Behçet's disease. Biomed Pharmacother 56:31-35.
165. Shimizu T, Ehrlich GE, Inaba G, Hayashi K (1979). Behçet disease (Behçet syndrome). Semin Arthritis Rheum 8:223-260.
166. Siepmann M, Kirch W (1997). Coronary anomaly in Behçet's syndrome. Rheumatol Int 17:39-42.
167. Silveira L, McGrath H (1992). Smoking controls symptomatology of Behçet's disease (abstract). Arthritis Rheum 35:12S.
168. Simsek H, Dundar S, Telatar H (1991). Treatment of Behçet disease with indomethacin. Int J Dermatol 30:54-57.
169. Sloper CM, Powell RJ, Dua HS (1999). Tacrolimus (FK506) in the treatment of posterior uveitis refractory to cyclosporine. Ophthalmology 106:723-728.
170. Sohn S, Bang D, Lee ES, Kwon HJ, Lee SI, Lee S (2001). Experimental studies on the antiviral agent famciclovir in Behçet's disease symptoms in ICR mice. Br J Dermatol 145:799-804.
171. Studd M, McCance DJ, Lehner T (1991). Detection of HSV-1 DNA in patients with Behçet's syndrome and in patients with recurrent oral ulcers by the polymerase chain reaction. J Med Microbiol 34:39-43.
172. Stuebiger N, Koetter I, Zierhut M (2000). Complete regression of retinal neovascularization after therapy with interferon alfa in Behçet's disease. Br J Ophthalmol 84:1437-1438.
173. Takeno M, Kariyone A, Yamashita N, Takiguchi M, Mizushima Y, Kaneoka H, et al. (1995). Excessive function of peripheral blood neutrophils from patients with Behçet's disease and from HLA-B51 transgenic mice. Arthritis Rheum 38:426-433.
174. Tan E, Chua SH, Lim JT (1999). Retrospective study of Behçet's disease seen at the National Skin Centre, Singapore. Ann Acad Med Singapore 28:440-444.
175. Tanaka T, Yamakawa N, Koike N, Suzuki J, Mizuno F, Usui M (1999). Behçet's disease and antibody titers to various heat-shock protein 60s. Ocul Immunol Inflamm 7:69-74.
176. Tessler HH, Jennings T (1990). High-dose short-term chlorambucil for intractable sympathetic ophthalmia and Behçet's disease. Br J Ophthalmol 74:353-357.
177. Treudler R, Orfanos CE, Zouboulis CC (1999). Twenty-eight cases of juvenile-onset Adamantiades-Behçet disease in Germany. Dermatology 199:15-19.
178. Tsuchida M, Mineshita S, Okonogi H (1997). The role of an uncommon type Streptococcus sanguis in the aetiology of Behçet's disease. Envir Hlth Prev Med 2:59-63.
179. Turan B, Gallati H, Erdi H, Gurler A, Michel BA, Villiger PM (1997). Systemic levels of the T cell regulatory cytokines IL-10 and IL-12 in Behçet's disease; soluble TNFR-75 as a biological marker of disease activity. J Rheumatol 24:128-132.
180. Tuzun Y, Yurdakul S, Cem MM, Ozyazgan Y, Hamuryudan V, Tuzun B, et al. (1996). Epidemiology of Behçet's syndrome in Turkey. Int J Dermatol 35:618-620.
181. Uzun S, Alpsoy E, Durdu M, Akman A (2003). The clinical course of Behçet's disease in pregnancy: a retrospective analysis and review of the literature. J Dermatol 30:499-502.
182. Verity DH, Vaughan RW, Madanat W, Kondeatis E, Zureikat H, Fayyad F, et al. (1999a). Factor V Leiden mutation is associated with ocular involvement in Behçet disease. Am J Ophthalmol 128:352-356.
183. Verity DH, Wallace GR, Vaughan RW, Kondeatis E, Madanat W, Zureikat H, et al. (1999b). HLA and tumour necrosis factor (TNF) polymorphisms in ocular Behçet's disease. Tissue Antigens 54:264-272.
184. Whallett AJ, Thurairajan G, Hamburger J, Palmer RG, Murray PI (1999). Behçet's syndrome: a multidisciplinary approach to clinical care. QJM 92:727-740
185. Yazici H (2002). Behçet's syndrome: where do we stand? Am J Med 112:75-76.
186. Yazici H, Barnes CG (1991). Practical treatment recommendations for pharmacotherapy of Behçet's syndrome. Drugs 42:796-804.
187. Yazici H, Ozyazgan Y (1999). Medical management of Behçet's syndrome. Dev Ophthalmol 31:118-131.
188. Yazici H, Chamberlain MA, Tuzun Y, Yurdakul S, Muftuoglu A (1984a). A comparative study of the pathergy reaction among Turkish and British patients with Behçet's disease. Ann Rheum Dis 43:74-75.
189. Yazici H, Tuzun Y, Pazarli H, Yurdakul S, Ozyazgan Y, Ozdogan H, et al. (1984b). Influence of age of onset and patient's sex on the prevalence and severity of manifestations of Behçet's syndrome. Ann Rheum Dis 43:783-789.
190. Yazici H, Tuzun Y, Tanman AB, Yurdakul S, Serdaroglu S, Pazarli H, et al. (1985). Male patients with Behçet's syndrome have stronger pathergy reactions. Clin Exp Rheumatol 3:137-141.
191. Yazici H, Basaran G, Hamuryudan V, Hizli N, Yurdakul S, Mat C, et al. (1996). The ten-year mortality in Behçet's syndrome. Br J Rheumatol 35:139-141.
192. Yazici H, Yurdakul S, Hamuryudan V (1998). Behçet's syndrome. In: Rheumatology. Klippel JH, Dieppe PA, editors. London: Mosby, pp. 1-6.
193. Yokota K, Hayashi S, Fujii N, Yoshikawa K, Kotake S, Isogai E, et al. (1992). Antibody response to oral streptococci in Behçet's disease. Microbiol Immunol 36:815-822.
194. Yucel AE, Kart-Koseoglu H, Akova YA, Demirhan B, Boyacioglu S (2004). Failure of infliximab treatment and occurrence of erythema nodosum during therapy in two patients with Behçet's disease. Rheumatology (Oxford) 43:394-396.
195. Yurdakul S, Yazici H, Tuzun Y, Pazarli H, Yalcin B, Altac M, et al. (1983). The arthritis of Behçet's disease: a prospective study. Ann Rheum Dis 42:505-515.
196. Yurdakul S, Gunaydin I, Tuzun Y, Tankurt N, Pazarli H, Ozyazgan Y, et al. (1988). The prevalence of Behçet's syndrome in a rural area in northern Turkey. J Rheumatol 15:820-822.
197. Yurdakul S, Mat C, Tuzun Y, Ozyazgan Y, Hamuryudan V, Uysal O, et al. (2001). A double-blind trial of colchicine in Behçet's syndrome. Arthritis Rheum 44:2686-2692.
198. Zouboulis CC, Kotter I, Djawari D, Kirch W, Kohl PK, Ochsendorf FR, et al. (1997). Epidemiological features of Adamantiades-Behçet's disease in Germany and in Europe. Yonsei Med J 38:411-422.
199. Zwirner NW, Fernandez-Vina MA, Stastny P (1998). MICA, a new polymorphic HLA-related antigen, is expressed mainly by keratinocytes, endothelial cells, and monocytes. Immunogenetics 47:139-148.